• June 3-6, 2024
  • San Diego Convention Center, California



Neuracle Genetics

Monday, June 03, 2024
Company Presentation
Company Presentation Theater 3
Neuracle Genetics, a clinical stage biotechnology company, is committed to improving patients' lives by harnessing the curative potential of gene therapy. We are developing innovative AAV gene therapy product candidates to treat retinal and neurological diseases with significant unmet needs. Leveraging our proprietary technologies, our product candidates are designed and optimized for safety and efficacy, with the goal of providing broader access to patients. Our lead product candidate, NG101, is designed to be the best-in-class AAV gene therapy for treating patients with wet age-related macular degeneration (wAMD). Our proprietary technologies enable the use of larger transgenes without compromising expression efficiency. Furthermore, our approach allows lower clinical doses than those of our competitors, potentially offering a superior safety profile while maintaining comparable efficacy. NG101 is currently in a Phase 1/2a clinical trial and is actively enrolling patients.
Neuracle Genetics
Company Website: http://neuraclegen.com/en/main/
Lead Product in Development: NG101 (currently in a Phase 1/2a clinical trial for the treatment of patients with wet age-related macular degeneration and is actively enrolling patients)
Number Of Unlicensed Products (For Which You Are Seeking Partners): 1

Company HQ City


Company HQ State


Company HQ Country

Korea, Republic of

CEO/Top Company Official

Jong Mook Kim

Development Phase of Primary Product

Phase I
Primary Speaker
Sunwoo Kim, CFA
Head of Business Development
Neuracle Genetics
Back to Session List

white squarewhite


Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.